<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="138009">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01304498</url>
  </required_header>
  <id_info>
    <org_study_id>V503-009</org_study_id>
    <secondary_id>GDS01C</secondary_id>
    <nct_id>NCT01304498</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Tolerability of V503 Versus GARDASIL</brief_title>
  <official_title>A Randomized, Double-Blinded, Controlled With GARDASIL (Human Papillomavirus Vaccine [Types 6, 11, 16, 18] (Recombinant, Adsorbed)), Phase III Clinical Trial to Study the Immunogenicity and Tolerability of V503 (9-Valent Human Papillomavirus (HPV) Vaccine) in Preadolescent and Adolescent Girls (9- to 15-year-old)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective:

      • To demonstrate that administration of V503 induces non-inferior Geometric Mean Titers
      (GMTs) (for serum anti-HPV16 and anti-HPV18) compared to GARDASIL.

      Secondary objectives:

        -  To evaluate the tolerability of V503 in 9-15 year-old girls.

        -  To summarize humoral immune response (anti-HPV 6, 11, 16, 18) induced by V503 or
           GARDASIL.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HPV 16 GMTs</measure>
    <time_frame>4 weeks post-dose 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>HPV 18 GMTs</measure>
    <time_frame>4 weeks post-dose 3</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>HPV 6 seroprotection rate</measure>
    <time_frame>Pre-vaccination (Day 1) and 4 weeks post-dose 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HPV 11 seroprotection rate</measure>
    <time_frame>Pre-vaccination (Day 1) and 4 weeks post-dose 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HPV 16 seroprotection rate</measure>
    <time_frame>Pre-vaccination (Day 1) and 4 weeks post-dose 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HPV 18 seroprotection rate</measure>
    <time_frame>Pre-vaccination (Day 1) and 4 weeks post-dose 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HPV 6 GMTs</measure>
    <time_frame>Pre-vaccination (Day 1) and 4 weeks post-dose 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HPV 11 GMTs</measure>
    <time_frame>Pre-vaccination (Day 1) and 4 weeks post-dose 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HPV 16 GMTs</measure>
    <time_frame>Pre-vaccination (Day 1) and 4 weeks post-dose 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HPV 18 GMTs</measure>
    <time_frame>Pre-vaccination (Day 1) and 4 weeks post-dose 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and percentage of subjects with injection-site adverse reactions</measure>
    <time_frame>From Day 1 to Day 15 following each vaccination</time_frame>
    <description>Injection-site adverse reactions: solicited (redness, swelling, and pain/tenderness/soreness) or unsolicited</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and percentage of subjects with systemic adverse events</measure>
    <time_frame>From Day 1 to Day 15 following each vaccination</time_frame>
    <description>Systemic adverse events: elevated temperature (≥37.8ºC) or other adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and percentage of subjects with serious adverse events</measure>
    <time_frame>From informed consent signature to 1 month after last vaccination (Day 1 to Month 7)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">600</enrollment>
  <condition>Human Papillomavirus</condition>
  <arm_group>
    <arm_group_label>V503</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>GARDASIL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>1 dose at Day 1, 1 dose at Month 2 and 1 dose at Month 6</intervention_name>
    <description>1 dose 0.5 mL</description>
    <arm_group_label>V503</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>1 dose at Day 1, 1 dose at Month 2 and 1 dose at Month 6</intervention_name>
    <description>1 dose 0.5 mL</description>
    <arm_group_label>GARDASIL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female from 9 to 15 years old.

          -  Good physical health.

        Exclusion Criteria:

          -  Known allergy to any vaccine component.

          -  History of severe allergic reaction.

          -  Thrombocytopenia or any coagulation disorder that would contraindicate intramuscular
             injections.

          -  Pregnant subject.

          -  Immunocompromised or immunodeficient subject.

          -  Splenectomy.

          -  Receipt of medication / vaccine that may interfere with study assessment.

          -  Fever

          -  History of a positive test for HPV, prior receipt of HPV vaccine or prior
             participation to HPV trial.

          -  Any condition that might interfere with study assessment.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie WEHRLEN-GRANDJEAN, MD</last_name>
    <role>Study Director</role>
    <affiliation>MCM Vaccines B.V.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site 0101</name>
      <address>
        <city>Antwerpen</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site 0103</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site 0102</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site 0203</name>
      <address>
        <city>Arhus</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site 0201</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site 0202</name>
      <address>
        <city>Hillerod</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site 0204</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site 0302</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site 0303</name>
      <address>
        <city>Jarvenpaa</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site 0305</name>
      <address>
        <city>Lahti</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site 0306</name>
      <address>
        <city>Pori</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site 0405</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site 0401</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site 0402</name>
      <address>
        <city>Latisana</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site 0404</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site 0403</name>
      <address>
        <city>Sassari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site 0501</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site 0502</name>
      <address>
        <city>Santiago de Compostela</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site 0503</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site 0504</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site 0505</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site 0602</name>
      <address>
        <city>Linkoping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site 0603</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site 0601</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site 0604</name>
      <address>
        <city>Umea</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi Pasteur MSD Investigational Site 0605</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 7, 2017</lastchanged_date>
  <firstreceived_date>February 24, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
